XSHE300003
Market cap2.66bUSD
Jan 27, Last price
10.37CNY
1D
-2.35%
1Q
-14.44%
Jan 2017
-42.16%
IPO
-10.29%
Name
Lepu Medical Technology Beijing Co Ltd
Chart & Performance
Profile
Lepu Medical Technology (Beijing) Co., Ltd. develops, produces, and sells medical devices and equipment. The company offers cardiovascular interventional products, such as coronary stents and balloons, catheters, guide wires, introducer sheaths, tourniquets, inflation devices, and PCI accessories; structural heart diseases products, including occluders, vascular plugs, delivery systems, and mechanical heart valves; cardiac rhythm management products, which include pacemakers, equipment, leads, and electrophysiology; off-pump coronary artery bypass grafting surgical cardiology products; and PTA balloons and guide wires peripheral interventional products. It also provides critical care products, such as vascular access products, needle free connectors, blood samplers, and pressure transducers; floor and suspended type digital subtraction angiography systems; in vitro diagnostic equipment and biomarkers; hemodialysis catheters and hollow fiber dialyzers; and general surgery products, including surgical staplers and endo surgery accessories. In addition, the company offers cardiovascular system drugs, such as antithrombotic, hypolipidemic, antihypertensive, antianginal, and heart failure treatment; ß-lactamase antibiotics and antifungal antimicrobial drugs; central nervous system drugs comprises painkillers and antidepressants; gastric/duodenal ulcer and chronic liver disease treatment drugs; respiratory system drugs; hypoproteinemia drugs; and activating blood circulation drugs. Further, it provides precision medicine, ECG telemonitoring, and cardiovascular disease consulting and management center services; medical S&T incubation and equity investment, and medical financial services; consultation, online pharmacy, and household medical equipment services; smart devices; and specialized hospital services for cardiovascular diseases, as well as involved in the co-construction of Cath lab. The company was founded in 1999 and is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 7,979,899 -24.78% | 10,609,442 -0.47% | |||||||
Cost of revenue | 4,985,175 | 7,198,412 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 2,994,724 | 3,411,030 | |||||||
NOPBT Margin | 37.53% | 32.15% | |||||||
Operating Taxes | 262,147 | 367,094 | |||||||
Tax Rate | 8.75% | 10.76% | |||||||
NOPAT | 2,732,577 | 3,043,936 | |||||||
Net income | 1,258,200 -42.91% | 2,203,779 28.18% | |||||||
Dividends | (635,057) | (487,986) | |||||||
Dividend yield | 2.12% | 1.17% | |||||||
Proceeds from repurchase of equity | (75,244) | (1) | |||||||
BB yield | 0.25% | 0.00% | |||||||
Debt | |||||||||
Debt current | 1,039,743 | 1,940,845 | |||||||
Long-term debt | 3,642,937 | 2,563,513 | |||||||
Deferred revenue | 3,711 | 183,748 | |||||||
Other long-term liabilities | 1 | 1 | |||||||
Net debt | (2,383,780) | (3,519,921) | |||||||
Cash flow | |||||||||
Cash from operating activities | 990,360 | 2,790,709 | |||||||
CAPEX | (844,669) | ||||||||
Cash from investing activities | (1,882,477) | ||||||||
Cash from financing activities | (292,918) | 412,749 | |||||||
FCF | 1,222,757 | 2,463,001 | |||||||
Balance | |||||||||
Cash | 4,495,959 | 5,744,493 | |||||||
Long term investments | 2,570,501 | 2,279,785 | |||||||
Excess cash | 6,667,465 | 7,493,806 | |||||||
Stockholders' equity | 13,597,555 | 13,974,914 | |||||||
Invested Capital | 15,438,019 | 13,069,364 | |||||||
ROIC | 19.17% | 25.02% | |||||||
ROCE | 13.43% | 16.42% | |||||||
EV | |||||||||
Common stock shares outstanding | 1,857,638 | 1,816,900 | |||||||
Price | 16.16 -29.65% | 22.97 1.50% | |||||||
Market cap | 30,019,433 -28.07% | 41,734,190 2.01% | |||||||
EV | 29,157,106 | 39,438,550 | |||||||
EBITDA | 3,508,284 | 3,899,502 | |||||||
EV/EBITDA | 8.31 | 10.11 | |||||||
Interest | 170,645 | 188,775 | |||||||
Interest/NOPBT | 5.70% | 5.53% |